Cocaine dependence has been linked closely to deficits in the dopamine (DA) brain system. ChnDnic cocaine users show impairments in cognitive processes known to be regulated by DA (e.g., working memory, decision-making). Consequently, recent medication development efforts have focused on DA-enhancing agents that might """"""""replace"""""""" cocaine and thereby normalize DA-related dysfunction, e.g., levodopa/carbidopa. These agents have shown clinical benefit in reducing cocaine;however there is a substantial subgroup of partial and non-responders for whom levodopa/carbidopa is not sufficient. In addition to DA, cocaine dependence is linked to deficits in serotonin (5-HT) system. Chronic cocaine users show impairments in processes know to be regulated by 5-HT (e.g., impulsivity). Our studies of 5-HT agents, including fluoxetine and citalopram, have shown some benefit in reducing cocaine use, although findings have been mixed across trials and patient subgroups. Since cocaine causes dysfunction in DA and 5-HT systems, an ideal replacement therapy would be expected to target both systems. The proposed study is the first placebo controlled study to examine a dualdeficit model by evaluating the combination of a DA and 5-HT agent for treatment of cocaine dependence. It is hypothesized that the co-administration of levodopa and citalopram will reduce cocaine use and increase periods of sustained abstinence substantially more than either medication alone or placebo. This study will also use novel Bayesian subgroup analyses to evaluate the utility of behavioral laboratory measures as predictors of treatment response. We expect that performance on a battery of neuropsychological tasks (working memory, decision-making, impulsivity) known to be associated with dopaminergic and serotonergic function, will be related to level of response to pharmacological treatment targeting these monoamine systems. Finally, relative changes in performance on these behavioral tasks after three weeks of treatment will be measured as potential mediators of medication response.

Public Health Relevance

This is a phase 2 clinical trial of a new combination pharmacotherapy approach for treatment of cocaine dependence. Co-administration of a dopamine- and serotonin-specific agent is expected to provide greater clinical benefit over single medication treatment. Performance on a set of behavioral tasks will be obtained at baseline and in-treatment to analyze as potential treatment moderators and mediators.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009262-19
Application #
8474732
Study Section
Special Emphasis Panel (ZDA1-EXL-T)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
19
Fiscal Year
2013
Total Cost
$166,330
Indirect Cost
$62,086
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Sharma, Jyoti; Rathnayaka, Nuvan; Green, Charles et al. (2016) Bradycardia as a Marker of Chronic Cocaine Use: A Novel Cardiovascular Finding. Behav Med 42:1-8
Vujanovic, Anka A; Rathnayaka, Nuvan; Amador, Christina D et al. (2016) Distress Tolerance: Associations With Posttraumatic Stress Disorder Symptoms Among Trauma-Exposed, Cocaine-Dependent Adults. Behav Modif 40:120-43
Azadeh, Shabnam; Hobbs, Brian P; Ma, Liangsuo et al. (2016) Integrative Bayesian analysis of neuroimaging-genetic data with application to cocaine dependence. Neuroimage 125:813-24
Vujanovic, Anka A; Wardle, Margaret C; Liu, Shijing et al. (2016) Attentional bias in adults with cannabis use disorders. J Addict Dis 35:144-53
Ramesh, Divya; Keyser-Marcus, Lori A; Ma, Liangsuo et al. (2015) Prevalence of traumatic brain injury in cocaine-dependent research volunteers. Am J Addict 24:341-7
Stotts, Angela L; Vujanovic, Anka; Heads, Angela et al. (2015) The role of avoidance and inflexibility in characterizing response to contingency management for cocaine use disorders: A secondary profile analysis. Psychol Addict Behav 29:408-13
Alcorn 3rd, Joseph L; Rathnayaka, Nuvan; Swann, Alan C et al. (2015) Effects of Intranasal Oxytocin on Aggressive Responding in Antisocial Personality Disorder. Psychol Rec 65:691-703
Stotts, Angela L; Northrup, Thomas F (2015) The Promise of Third-Wave Behavioral Therapies in the Treatment of Substance Use Disorders. Curr Opin Psychol 2:75-81
Ma, Liangsuo; Steinberg, Joel L; Cunningham, Kathryn A et al. (2015) Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls. Neuroimage Clin 7:837-47
Dias, Nadeeka R; Lane, Scott D; Rathnayaka, Nuvan et al. (2015) Demographic and psychological factors associated with lifetime cocaine use: An exploratory factor analysis of baseline questionnaires. Addict Disord Their Treat 14:70-77

Showing the most recent 10 out of 79 publications